RHRonaldo Campos Hallal

Ronaldo Campos Hallal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ronaldo Campos Hallal has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HIV/AIDS in the state of Amazonas, Brazilian Amazon: decentralization, third-party support and community action

    by Adele Schwartz Benzaken, Zeca Manuel Salimo, Maria Eduarda Leão Farias, Aretha Gomes Omena, Ronaldo Campos Hallal, Renato Chuster Hamed Humar, Beto de Jesus, Izabella Picinin Safe, Marcus Vinícius Guimarães Lacerda

    Amazonas is Brazil’s largest state and a paradigmatic tropical medicine setting: vast territories connected mainly by rivers, high cultural and linguistic diversity, and multiple co-endemic infections. The state comprises 62 municipalities and roughly 4.3 million inhabitants, with approximately half of its inhabitants residing in Manaus, the capital, where specialized human immunodeficiency virus (HIV ) services have historically been concentrated. However, the HIV/ acquired immunodeficiency syndrome (AIDS) epidemic has shown sustained interiorization beyond the capital and a high AIDS mortality coefficient, reflecting late diagnosis and gaps in retention in care. Over the last decade, expanded testing, rapid initiation of antiretroviral therapy (ART), the introduction of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), HIV self-testing, and decentralized municipal services in partnership with third parties, such as the AIDS Healthcare Foundation (AHF), have coincided with declining AIDS mortality, yet heterogeneity across municipalities remains pronounced, including in predominantly Indigenous areas and border regions. This review synthesizes key programmatic inflection points and highlights the complementary roles of the public sector, third-party organizations, and civil society in implementing combination prevention, improving linkage to care and monitoring loss to follow-up. In this narrative review, we argue that HIV in the Brazilian Amazon should be understood through a syndemic lens encompassing tuberculosis co-infection, mobility and geographic dispersion, and that progress toward 95-95-95-aligned targets will require differentiated service delivery, integrated tuberculosis (TB)/HIV strategies, and supply-chain and workforce resilience tailored to riverine, rural and Indigenous contexts.

  • Open Access

    Price as a challenge to the sustainability of the universal access policy to antiretrovirals in SUS: the case of dolutegravir

    by Luciana de Melo Nunes Lopes, Carolinne Thays Scopel, Ronaldo Campos Hallal, Gustavo Luís Meffe Andreoli, Draurio Barreira, Marcela Vieira Freire, Francisco Alisson Paula de França

    The price of antiretrovirals (ARVs) continues to be a challenge to guarantee universal, comprehensive, and equitable pharmaceutical services. This article aimed to analyze the acquisition of the most widely used ARV in Brazil, comparing national and international prices. Our study conducted a documentary analysis of the history of the national procurement of dolutegravir (DTG) from 2017 to 2023. The price comparison was based on reports from the Clinton Health Access Initiative (CHAI), considering exchange rate and inflation variations. In 2022, generic versions from Farmanguinhos and Lafepe were distributed, but a patent barrier restricted the procurement from Lafepe. A major difference was found between national and international prices, even with the entry of generics into the Brazilian market; in 2023, the price of international generics was almost 12 times lower than that of the national procurement. The DTG case highlights the importance of monitoring prices, patent barriers, and local production, and of becoming familiar with the structure of production costs in order to negotiate fair prices and ensure the sustainability of the national pharmaceutical assistance policy.

  • Open Access

    Preço como um desafio à sustentabilidade da política de acesso universal a antirretrovirais no SUS: o caso dolutegravir

    by Luciana de Melo Nunes Lopes, Carolinne Thays Scopel, Ronaldo Campos Hallal, Gustavo Luís Meffe Andreoli, Draurio Barreira, Marcela Vieira Freire, Francisco Alisson Paula de França

    Resumo O preço dos antirretrovirais (ARV) continua sendo um desafio para a garantia da assistência farmacêutica universal, integral e igualitária. O artigo teve como objetivo analisar a aquisição do ARV mais utilizado atualmente no Brasil, comparando preços nacionais e internacionais. Foi realizada análise documental do histórico de aquisição nacional do dolutegravir (DTG) entre 2017 e 2023. A comparação de preços baseou-se em relatórios da Clinton Health Access Initiative (CHAI), considerando variações cambiais e da inflação. Em 2022, versões genéricas de Farmanguinhos e Lafepe foram distribuídas, mas uma barreira patentária restringiu a aquisição junto ao Lafepe. Houve grande diferença entre preços nacionais e internacionais, mesmo com a entrada de genéricos no mercado brasileiro: em 2023, o preço de genéricos internacionais foi quase 12 vezes menor que o de aquisição nacional. O caso do DTG evidencia a importância do monitoramento dos preços, das barreiras patentárias, da produção local e do conhecimento da estrutura dos custos de produção para a negociação de preços justos e garantia da sustentabilidade da política nacional de assistência farmacêutica.